First-in-human, open label, multicenter phase I of IPH4102, first-in-class humanized anti-KIR3DL2 monoclonal antibody, in relapsed/refractory cutaneous T-cell lymphomas. Bagot, M., Duvic, M., Vermeer, M., Porcu, P., Whittaker, S., Ram-Wolff, C., Paiva, C., Marie-Cardine, A., Bonnafous, C., Paturel, C., Moriette, F., Zerbib, R., Bensussan, A., Sicard, H., Pilz, K., Kim, Y. H. AMER SOC CLINICAL ONCOLOGY. 2016

View details for DOI 10.1200/JCO.2016.34.15_suppl.TPS2591

View details for Web of Science ID 000404665403190